UNICREDIT BANK/CALL/BIOGEN IDEC/300/0.1/18.12.24 | Real-time BOERSE MUENCHEN 01:12:12 29/05/2024 am IST | ||
| 0.51 EUR | -7.27% |
|
| Current month | +41.67% | ||
| 1 month | +82.14% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 0.51 | -7.27% |
| 27/24/27 | 0.55 | 0.00% |
| 24/24/24 | 0.55 | +10.00% |
| 23/24/23 | 0.5 | -1.96% |
| 22/24/22 | 0.51 | -20.31% |
Real-time BOERSE MUENCHEN
Last update May 29, 2024 at 01:12 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HC3LKJ |
| ISIN | DE000HC3LKJ9 |
| Date issued | 27/01/2023 |
| Strike | 300 $ |
| Maturity | 18/12/2024 (204 Days) |
| Parity | 10 : 1 |
| Emission price | 6.72 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.77 € |
|---|---|
| Lowest since issue | 0.13 € |
| Spread | 0.02 € |
| Spread % | 3.70% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
218.7
USD
Average target price
286.1
USD
Spread / Average Target
+30.78%
- Stock Market
- Warrants
- Warrant
